Invitrocue currently operates in Singapore, Australia, China, Hong Kong and Germany,
and is listed on Australian Securities Exchange under the ticker IVQ.
Invitrocue has developed a unique 3D cell-based scaffolding technology that mimics human organ samples for using in the field of infectious diseases.
In 2016, the company expanded its work in liver disease to the field of oncology. The technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients (personalised medicine).
News & Events
Invitrocue Appoints Renowned Oncology Researcher Professor Jesús García-Foncillas as Clinical Advisor
EXCERPT: January 15, 2019 – Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the appointment of Professor Jesús García-Foncillas as Clinical Advisor of Invitrocue. Professor Jesús is an experienced oncology researcher with 25 years of experience in cancer diagnosis and treatment. He holds multiple executive leadership positions at “Fundacion […]Read More
Invitrocue Appoints Professor Masakazu Toi as Clinical Advisor
EXCERPT: January 11, 2019 – Invitrocue Limited (ASX: IVQ), a leader healthcare bio-analytic solutions provider, is pleased to announce the appointment of Professor Masakazu Toi as Clinical Advisor of Invitrocue. A renowned oncology expert having held various roles as healthcare provider, scholar, and opinion leader, Professor Toi brings strong clinical oncology knowledge and experience especially […]Read More
Invitrocue announced Board Changes
EXCERPT: January 9, 2019 – Invitrocue Limited (ASX : IVQ), a leading healthcare bio-analytic solutions provider, announces the appointment of Dr. Steven Fang as Chairman of the Company’s Board of Directors with immediate effect. Dr. Fang is a co-founder and the Executive Director of Invitrocue with more than 20 years’ experience in leading and building successful […]Read More
Invitrocue – 50 Top Investment Ideas for 2019 – The Australian Newspaper
We are proud to share that Invitrocue has been mentioned as one of the 50 top investment ideas for 2019 in The Australian, the biggest-selling national newspaper in Australia! Healthcare bio-analytics play (21) Invitrocue (IVQ) has made significant progress with its flagship product Onco-PDO, a cell-based scaffolding technology that gathers a patient’s cancer information to guide […]Read More
Invitrocue’s Steven Fang: Insights into the Asian Biopharma Market
Invitrocue’s Steven Fang: Insights into the Asian Biopharma Market Published: Nov 29, 2018 By Mark Terry Steven Fang, Executive Director of Invitrocue It comes as no surprise to anyone that China is considered a big and booming potential market for drugs and medicines—or anything else, for that matter. The country has 1.3 billion people and a growing […]Read More
Health Investor Asia – The Serial Entrepreneur: Interview with Steven Fang
Originally published in Health Investor Asia – view PDF article here. Steven Fang understands how to set up a healthcare company. Not only is he chief executive and founder of ASX-listed oncology company Invitrocue, he was also the founder of Singapore-based Cordlife Group, a healthcare company which provides cord blood and cord lining banking services. […]Read More
Dr Lindner as Europe CEO and Prof Waugh as Senior Advisor
Dr Lindner as Europe CEO and Prof Waugh as Senior AdvisorRead More
Biotech Investment Summit @ Singapore
Date: 2nd November at 11.30am Venue: One Farrer Hotel, 1 Farrer Park Station Road, Singapore 217562 Dr Steven Fang will be speaking about “Strategic Investments in R/D to Accelerate Global Growth of Biotechnology Companies” detailing the following: Investment opportunities and partnerships in the Chronic disease segment Unique and advanced technologies showcase Expanding plan in Asia Co Located […]Read More